|Bid||3.0000 x 800|
|Ask||3.1000 x 1300|
|Day's range||2.7800 - 3.2900|
|52-week range||2.1000 - 15.0000|
|Beta (5Y monthly)||1.90|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Regulatory and other pipeline updates from Zogenix (ZGNX) and Regeneron (REGN) are among a few key highlights from the biotech sector during the past week.
The FDA agrees to the initiation of rolling submission of Gamida's (GMDA) BLA for its lead blood cancer candidate, omidubicel. The stock rises more than 22% on in response.
Please be advised that this call is being recorded at Gamida Cell's request. Now, I would like to introduce your host for today's conference, Mr. Josh Hamermesh, chief business officer. Welcome to today's call, during which we will provide an update on the company and review our financial results for the third quarter of 2021.